Search results for "cache"

showing 10 items of 79 documents

Differentiation of Murine C2C12 Myoblasts Strongly Reduces the Effects of Myostatin on Intracellular Signaling

2020

Alongside in vivo models, a simpler and more mechanistic approach is required to study the effects of myostatin on skeletal muscle because myostatin is an important negative regulator of muscle size. In this study, myostatin was administered to murine (C2C12) and human (CHQ) myoblasts and myotubes. Canonical and noncanonical signaling downstream to myostatin, related ligands, and their receptor were analyzed. The effects of tumorkines were analyzed after coculture of C2C12 and colon cancer-C26 cells. The effects of myostatin on canonical and noncanonical signaling were strongly reduced in C2C12 cells after differentiation. This may be explained by increased follistatin, an endogenous blocke…

Muscle Fibers Skeletallcsh:QR1-502lihaksetlcsh:MicrobiologyArticleTGF-BETA SUPERFAMILYCell LineMyoblastsMicetumorkineCell Line TumorfollistatinAnimalsHumansCANCER CACHEXIAskeletal muscleMUSCLE ATROPHYlihassolutSmadsoluviestintäRECEPTORCell DifferentiationIN-VITROMyostatinmusculoskeletal systemMAPKActivinsLEUKEMIA INHIBITORY FACTORACTIVIN-AinflammationCulture Media ConditionedCELLSPROTEIN-SYNTHESISmyotubeGROWTH1182 Biochemistry cell and molecular biologyproteiinit3111 BiomedicinecocultureSignal Transduction
researchProduct

Prognostic Value of Sarcopenia in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil

2021

Sarcopenia is common in metastatic colorectal cancer (mCRC), increases the risk of treatment-related toxicity and reduces survival. Trifluridine/tipiracil (TT) chemotherapy significantly improved survival in refractory mCRC patients, but the prognostic and predictive role of pretherapeutic sarcopenia and variation in the skeletal muscle index (SMI) during this treatment has not been investigated so far. In this retrospective, observational study, clinical data on mCRC patients treated with TT at six cancer centres in Poland were collected. Computed tomography (CT) scans acquired at the time of initiation of TT (CT1) and on the first restaging (CT2), were evaluated. SMI was assessed based on…

Oncologymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentTrifluridineArticletrifluridine/tipiracilsarcopeniachemistry.chemical_compoundCarcinoembryonic antigenInternal medicineMedicineTipiracilChemotherapyPerformance statusbiologybusiness.industrymetastatic colorectal cancerRCancerGeneral Medicinemedicine.diseasechemistrySarcopeniabiology.proteinMedicinebusinessmedicine.drugcancer cachexiaJournal of Clinical Medicine
researchProduct

Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: a systematic review.

2014

Abstract Background/objectives Cachexia affects ∼80% of pancreatic cancer patients. An international consensus defines cachexia as an ongoing loss of skeletal muscle mass (sarcopenia) with or without loss of fat, which impairs body functioning and cannot be reversed by conventional nutritional measures. Weight loss percentage and elevated inflammation markers have been employed to define this condition earlier. This review aimed to assess the prevalence and consequences of cachexia and sarcopenia on survival in patients with pancreatic ductal adenocarcinoma. Methods The systematic review was performed by searching the articles with preset terms published in PubMed and Cochrane Database unti…

Oncologymedicine.medical_specialtySarcopeniaCachexiaEndocrinology Diabetes and MetabolismOverweightCachexiaWeight lossInternal medicinePancreatic cancerWeight LossmedicinePrevalenceHumansSarcopenic obesityHepatologybusiness.industryConfoundingGastroenterologymedicine.diseasePrognosismusculoskeletal systemPancreatic NeoplasmsSurvival RateCachexia/diagnosis/epidemiology/*etiology; Carcinoma Pancreatic Ductal/*complications/mortality; Humans; Pancreatic Neoplasms/*complications/mortality; Prevalence; Prognosis; Sarcopenia/diagnosis/epidemiology/*etiology; Survival Rate; Weight LossSarcopeniaAdenocarcinomamedicine.symptombusinessCarcinoma Pancreatic Ductal
researchProduct

Beyond Physical Exercise: The Role of Nutrition, Gut Microbiota and Nutraceutical Supplementation in Reducing Age-related Sarcopenia

2021

Sarcopenia is a commonly prevalent geriatric condition mainly characterized by progressive loss of the skeletal muscle mass that results in noticeably reduced muscle strength and quality. Most of the geriatric population above 60 years of age are overweight, leading to the accumulation of fat in the muscles resulting in abated muscle function. The increased loss of muscle mass is associated with high rates of disability, poor motility, frailty and mortality. The excessive degeneration of muscles is now also being observed in middle-aged people. Therefore, geriatrics has recently started shifting towards the identification of early stages of the disability in order to expand the life span o…

Pulmonary and Respiratory MedicineGerontologySarcopeniamedicine.medical_specialtySettore MED/09 - Medicina InternaNutritional Supplementationmuscle maNutritional StatusPhysical exercisemalnutritionOverweightGut floracachexiaCachexiamedicineHumansMuscle StrengthMuscle SkeletalNutritionAgedGeriatricsbiologyexercisebusiness.industryMuscle massMiddle Agedmedicine.diseasebiology.organism_classificationGastrointestinal MicrobiomeMalnutritionAgeingSarcopeniaDietary SupplementsPediatrics Perinatology and Child Healthmedicine.symptombusinessnutrition.
researchProduct

Hsp60 levels and mitochondrial biogenesis in skeletal muscle after endurance training

Settore BIO/16 - Anatomia UmanaSKELETAL MUSCLE MUSCLE WASTING CACHEXIA ENDURANCE TRAINING Hsp60 PGC1alpha.
researchProduct

Procedimento per la sintesi di esosomi contenenti proteine da shock termico e loro uso per il trattamento della atrofia muscolare e della cachessia

2018

Settore BIO/16 - Anatomia Umanacachexia skelethal muscle exosomes extracellular vescicles Hsp60
researchProduct

Development of a new anti-cachectic drug based on nano-vesicles

2020

Settore CHIM/09 - Farmaceutico Tecnologico ApplicativoexosomeExtracellular vesiclecell engineeringcachexia
researchProduct

IPERSENSIBILITÀ AL GLUTINE NELL’ANZIANO. PRESENTAZIONE DI UN CASO CLINICO

2015

La celiachia è una malattia immunomediata scatenata dall’ingestione di glutine che, in soggetti geneticamente predisposti, determina un processo infiammatorio intestinale con conseguente malassorbimento e manifesta-zioni extraintestinali. Fino ad alcuni anni fa era considerata una patologia rara, tipica dell’età infantile; lo scenario epidemiologico della celiachia, oggi, è totalmente cambiato, grazie anche all’introduzione di test sierologici ad elevata sensibilità e specificità come gli anticorpi anti-endomisio (EMA) e gli anticorpi anti-transglutaminasi tissutale (tTG). Studi epidemiologici basati sull’impiego dei test sierologici hanno dimostrato che la diagnosi di celiachia viene sempr…

Settore MED/09 - Medicina Internaceliachia ipersensibilità al glutine cachessia malassorbimento
researchProduct

Celiac disease in older persons: A case of seronegative disease

2017

A 68-year-old man with a history of smoking (former smoker of 40 cigarettes per day), euthyroid goiter, deep vein thrombosis and depression, came to our attention for weakness, cachexia, abdominal bloating and diarrhea lasting for almost six months. Furthermore, he had lost about 25 kilograms of weight in the last year and was bedridden for three months. Combining the results of serological, histopathological and genetic tests, he was diagnosed with a seronegative celiac disease. Gluten-free diet, combined with nutritional supplements and physical therapy, improved his clinical condition and allowed the recovery of weight and the walking ability. Celiac disease might be suspected in elderly…

Settore MED/09 - Medicina Internagluten-free dietmalnutritioncachexiaelderlyceliac disease
researchProduct

TERAPIA DELLA SARCOPENIA

2014

La sarcopenia e la cachessia sono i disordini muscolari più comune negli adulti. La principale differenza tra le due condizioni è che, a livello istologico, la sarcopenia rappresenta una condizione età correlata che si accompagna a neurodegenerazione, mentre la cachessia è una malattia infiammatoria del muscolo, che è associata a perdita di tessuto adiposo e ad anoressia. E’ stato dimostrato che entrambe le condizioni, nonostante le differenze nella etiologia e fisiopatologia, rispondono positivamente a trattamenti che aumentano la massa e la forza muscolare. Il gold standard attuale della terapia della sarcopenia è l'esercizio fisico. Inoltre, esistono una serie di farmaci che sono disponi…

Settore MED/09 - Medicina Internasarcopenia fragilità cachessia invecchiamento anoressiasarcopenia frailty cachexia aging anorexia
researchProduct